CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of urothelial bladder cancer.
  
  LEARNING OBJECTIVES

  • Consider available data supporting anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
  • Evaluate the efficacy of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this treatment strategy.
  • Recognize how biological and patient-specific factors influence the selection and sequencing of treatment for metastatic UBC.
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in practice.
  • Appreciate the biological rationale for combining anti-PD-1/PD-L1 antibodies with chemotherapy or antibody-drug conjugates, and assess the current and future role of these regimens in the care of patients with previously untreated metastatic UBC.
  • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds, such as antibody-drug conjugates and tyrosine kinase inhibitors, for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
  • Interrogate clinical trial findings with HER2-directed therapies for advanced UBC, and evaluate the future utility of these agents in the care of appropriately selected patients.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with approved and emerging systemic therapies for metastatic UBC.
  • Develop an understanding of the biological rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for patients with NMIBC, MIBC and metastatic UBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCOGU24/Bladder/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Matthew Milowsky, MD, FASCO
  George Gabriel and Frances Gable Villere Distinguished Professor
  Vice Chief for Research and Education
  Section Chief, Genitourinary Oncology
  UNC Division of Oncology
  Co-Lead, Clinical and Translational Research
  Co-Director, Urologic Oncology Program
  UNC Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  Contracted Research: Accuray, Acrivon Therapeutics, ALX Oncology,Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, MorphoSys, Novartis, Seagen Inc; Nonrelevant Financial Relationships: Alliance for Clinical Trials in Oncology, Alliance Foundation Trials LLC, Elsevier (Co-Editor-in-Chief, Clinical Genitourinary Cancer), Hoosier Cancer Research Network Inc, Medscape, The Prostate Cancer Clinical Trials Consortium.
  
  Peter H O'Donnell, MD
  Associate Professor of Medicine
  Department of Medicine
  The University of Chicago
  Chicago, Illinois
  
  Advisory Committees: Merck, Seagen Inc; Consulting Agreements: Adept Field Solutions, AmerisourceBergen, Astellas, Axiom Healthcare Strategies, Curio Science, Custom Learning Designs (CLD), EMD Serono Inc, Health Advances, Merck, Pfizer Inc, Seagen Inc, Vaniam Group, Vida Ventures LLC; Contracted Research (to Institution): Acerta Pharma — A member of the AstraZeneca Group, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Seagen Inc; Data and Safety Monitoring Boards/Committees: Dragonfly Therapeutics, G1 Therapeutics Inc, Janssen Biotech Inc, Nektar; Sponsored Travel: Astellas, Curio Science, Seagen Inc; Nonrelevant Financial Relationships: Advarra, FirstWord Pharma, Great Debates &Updates, Hart Wagner LLP, IntrinsiQ Specialty Solutions, ISMIE, Med Learning Group, MJH Life Sciences, NAMCP, O’Brien & Ryan LLP, Parexel, PeerView, PharmaVision UK, PRIME Education LLC, The Institute for Enquiring Minds.
  
  Jonathan E Rosenberg, MD
  Chief, Genitourinary Medical Oncology Service
  Division of Solid Tumor Oncology
  Enno W Ercklentz Chair
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committees: Astellas, Seagen Inc, Tyra Biosciences; Consulting Agreements: Aadi Bioscience, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Emergence Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Imvax Inc, Infinity Pharmaceuticals Inc, Jiangsu Hengrui Medicine Co Ltd, Lilly, Merck, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Speakers Bureaus: EMD Serono Inc, Pfizer Inc; Nonrelevant Financial Relationships: Clinical Care Options, Medscape, MJH Life Sciences.
  
  Arlene Siefker-Radtke, MD
  Professor
  Department of Genitourinary Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR
  Evan Y Yu, MD
  Section Head, Medical Oncology, Clinical Research Division
  Fred Hutchinson Cancer Center
  Medical Director, Clinical Research Support
  Fred Hutchinson Cancer Research Consortium
  Professor of Medicine
  Division of Hematology and Oncology, Department of Medicine
  University of Washington School of Medicine
  Seattle, Washington
  
  Consulting Agreements: Aadi Bioscience, Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Oncternal Therapeutics; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Seagen Inc, Surface Oncology, Taiho Oncology Inc, Tyra Biosciences.
  
  SURVEY PARTICIPANTS
  Terence Friedlander, MD — Advisory Committees: Aadi Bioscience, Astellas, Seagen Inc; Consulting Agreement: Merck; Contracted Research: Bristol Myers Squibb, Roche Laboratories Inc, Seagen Inc, Trishula Therapeutics Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Elizabeth R Plimack, MD, MS — Advisory Committees and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Eisai Inc, EMD Serono Inc, IMV Inc, Merck, Pfizer Inc, Seagen Inc, Synthekine; Contracted Research: Merck.
  
  VIDEO PARTICIPANT
  Priyanka Sharma, MD — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genzyme Corporation, Gilead Sciences Inc, GSK, Merck, Novartis, Pfizer Inc, Sanofi; Contracted Research: Gilead Sciences Inc, Merck, Novartis; Stock Options/Stock ― Public Companies: Amgen Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Sanofi.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: February 2024
  Expiration date: February 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.